Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
ConclusionsDuring long-term treatment, teneligliptin was generally well tolerated in patients with any stage of renal impairment from normal to end-stage renal disease, including those on dialysis, and improved glycemic control.Trial Registration NumberJapic CTI-153047.FundingMitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co, Ltd.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Dialysis | Drugs & Pharmacology | Endocrinology | Heart | Japan Health | Pharmaceuticals | Study | Urology & Nephrology